MA54058A - Compositions et méthodes de traitement de l'endométriose interne et de l'endométriose rectovaginale - Google Patents
Compositions et méthodes de traitement de l'endométriose interne et de l'endométriose rectovaginaleInfo
- Publication number
- MA54058A MA54058A MA054058A MA54058A MA54058A MA 54058 A MA54058 A MA 54058A MA 054058 A MA054058 A MA 054058A MA 54058 A MA54058 A MA 54058A MA 54058 A MA54058 A MA 54058A
- Authority
- MA
- Morocco
- Prior art keywords
- endometriosis
- compositions
- treatment
- methods
- internal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862752100P | 2018-10-29 | 2018-10-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA54058A true MA54058A (fr) | 2021-09-08 |
Family
ID=68461757
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA054058A MA54058A (fr) | 2018-10-29 | 2019-10-29 | Compositions et méthodes de traitement de l'endométriose interne et de l'endométriose rectovaginale |
Country Status (6)
Country | Link |
---|---|
US (1) | US20220117969A1 (fr) |
EP (1) | EP3873465A2 (fr) |
AU (1) | AU2019373349A1 (fr) |
CA (1) | CA3117092A1 (fr) |
MA (1) | MA54058A (fr) |
WO (1) | WO2020089190A2 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115232144B (zh) * | 2021-04-22 | 2024-04-02 | 长春金赛药业有限责任公司 | 含氮稠环类衍生物、药物组合物及其制备方法和应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL360294A1 (en) | 2000-07-05 | 2004-09-06 | Yamanouchi Pharmaceutical Co.Ltd. | Propane-1,3-dione derivatives |
US7300935B2 (en) | 2003-01-29 | 2007-11-27 | Takeda Pharmaceutical Company | Thienopyrimidine compounds and use thereof |
BRPI0412314B8 (pt) | 2003-07-07 | 2021-05-25 | Neurocrine Biosciences Inc | composto 3-[2(r)-{hidroxicarbonilpropil-amino}-2-feniletil]-5-(2-flúor-3-metoxifenil)-1-[2-flúor-6-(trifluorometil)benzil]-6-metil-pirimidina-2,4(1h,3h)-diona, composição farmacêutica compreendendo dito composto e uso do mesmo para o tratamento de uma condição relacionada ao hormônio sexual |
ES2398917T7 (es) | 2005-10-19 | 2022-10-26 | Kissei Pharmaceutical | Derivado heterocíclico condensado, composición medicinal que contiene el mismo, y uso medicinal del mismo |
SG183243A1 (en) | 2010-02-10 | 2012-09-27 | Kissei Pharmaceutical | Salt of fused heterocyclic derivative and crystal thereof |
WO2014042176A1 (fr) | 2012-09-14 | 2014-03-20 | キッセイ薬品工業株式会社 | Procédé de production d'un dérivé hétérocyclique fusionné, et production intermédiaire |
EP3498280B1 (fr) * | 2016-08-08 | 2024-04-03 | Kissei Pharmaceutical Co., Ltd. | Administration et dosage d'un agent thérapeutique pour l'endométriose |
CN110312512B (zh) * | 2016-09-30 | 2023-05-09 | 梦欧文科学有限责任公司 | 用于治疗子宫肌瘤和子宫内膜异位症的方法 |
-
2019
- 2019-10-29 AU AU2019373349A patent/AU2019373349A1/en active Pending
- 2019-10-29 US US17/289,418 patent/US20220117969A1/en active Pending
- 2019-10-29 CA CA3117092A patent/CA3117092A1/fr active Pending
- 2019-10-29 EP EP19798018.8A patent/EP3873465A2/fr active Pending
- 2019-10-29 WO PCT/EP2019/079448 patent/WO2020089190A2/fr unknown
- 2019-10-29 MA MA054058A patent/MA54058A/fr unknown
Also Published As
Publication number | Publication date |
---|---|
US20220117969A1 (en) | 2022-04-21 |
WO2020089190A2 (fr) | 2020-05-07 |
WO2020089190A3 (fr) | 2020-06-18 |
CA3117092A1 (fr) | 2020-05-07 |
AU2019373349A1 (en) | 2021-05-20 |
EP3873465A2 (fr) | 2021-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA45539A (fr) | Dihydropyranopyrimidines pour le traitement d'infections virales | |
MA49069A (fr) | Procédés et compositions pour le traitement d'apnée du sommeil | |
MA52861A (fr) | Méthodes et compositions pour le traitement de l'apnée du sommeil | |
MA45192A (fr) | Traitement d'association | |
MA43135A (fr) | Compositions et méthodes pour le du traitement du cancer | |
MA52232A (fr) | Inhibiteurs hétérobicycliques de mat2a et leurs méthodes d'utilisation pour le traitement du cancer | |
MA49144A (fr) | Polythérapies pour le traitement du cancer | |
MA45481A (fr) | Utilisation d'exosomes pour le traitement de maladies | |
MA45798A (fr) | Compositions et procédés d'inhibition de masp-3 pour le traitement de maladies et troubles divers | |
MA44083A (fr) | Composés de biarylmonobactame pour le traitement d'infections bactériennes | |
IL281277A (en) | Preparations and methods for treating viral infections | |
MA49576A (fr) | Compositions et méthodes pour le traitement d'infections fongiques | |
MA48637A (fr) | Polythérapies pour le traitement du cancer | |
MA51306A (fr) | Compositions et procédés améliorés pour le traitement du déficit en ornithine transcarbamylase | |
MA50409A (fr) | Polythérapies pour le traitement du cancer | |
MA52631A (fr) | Compositions et méthodes pour le traitement de la maladie de parkinson | |
MA51056A (fr) | Compositions et méthodes pour le traitement d'affections métaboliques | |
MA52790A (fr) | Compositions et méthodes de traitement de la thrombopénie immune | |
MA53873A (fr) | Compositions et procédés pour le traitement de la presbytie | |
MA45552A (fr) | Compositions destinées au traitement de l'amylose | |
MA47362A (fr) | Anticorps anti-tnf, compositions et méthodes pour le traitement du rhumatisme psoriasique actif | |
SG11202103567RA (en) | Methods of treatment of inflammatory conditions and associated infections | |
MA45226A (fr) | Compositions et méthodes de traitement ou de prévention d'affections liées à l'oxalate | |
MA44864A (fr) | Trithérapie pour le traitement d'une maladie intestinale inflammatoire | |
MA43825A (fr) | Schémas posologiques pour le traitement d'infections fongiques |